Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 606 across all filing types
Latest filing 2024-05-15 Capital/Financing Update
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Amendment to Open Offer timetable
Capital/Financing Update Classification · 1% confidence The document is an RNS announcement from Genedrive PLC, dated May 15, 2024. The content explicitly discusses an 'Amendment to Open Offer timetable and revision to REX Offer timetable' related to a 'Fundraising'. It details specific dates and times for various steps in a capital raising process (Placing, Open Offer, General Meeting). This clearly relates to the company's financing activities and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). Although it is an RNS announcement, the core subject matter is the financing event itself, not just a general regulatory update or a report publication announcement.
2024-05-15 English
Publication of Circular and Notice of GM
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement from Genedrive PLC dated May 14, 2024. The title explicitly states 'Publication of Circular and Notice of General Meeting'. It details a fundraising effort involving a Placing and an Open Offer, which is conditional on passing Resolutions at a General Meeting scheduled for May 31, 2024. The document announces the publication of a Circular which contains the notice for this General Meeting and provides details about the Open Offer timetable. Since the core purpose of this announcement is to inform the market about the upcoming General Meeting (AGM/EGM related event) and the associated documentation (Circular), the most appropriate classification is AGM-R (AGM Information), as it directly relates to materials shared for a general meeting, even though it is framed as an announcement of publication. It is not a DEF 14A (Remuneration) or a PSI (Proxy Solicitation), but rather an announcement concerning the meeting itself and related capital actions. Given the focus on the Notice of General Meeting, AGM-R is the best fit among the specific options, although RPA or RNS could also apply if the content was purely administrative. However, the content is substantive regarding the meeting and capital structure changes tied to it.
2024-05-14 English
Completion of placing
Capital/Financing Update Classification · 1% confidence The document is an RNS announcement dated May 10, 2024, detailing the 'Completion of Placing' as part of a larger 'Fundraising' effort involving a Firm Placing, Conditional Placing, REX Offer, and Open Offer. It discusses the allotment of new ordinary shares, issue price, gross proceeds, and conditions related to a General Meeting. The text explicitly mentions that a Circular containing a notice for the General Meeting 'will be posted to shareholders over the coming days' and that 'A further announcement will confirm the posting date... and the availability of the Circular'. This structure—announcing the completion of a financing event and referencing the upcoming publication of detailed shareholder materials (like the Circular for the Open Offer/GM)—strongly indicates this is a regulatory announcement about a corporate action rather than the final detailed report itself. Since it is a formal announcement published via RNS regarding a significant capital event (share issue/fundraising), the most appropriate classification is 'Capital/Financing Update' (CAP). While it is an RNS filing, CAP is more specific to the content than the general RNS fallback.
2024-05-10 English
Proposed REX Retail Offer
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Genedrive PLC, dated May 9, 2024, disseminated via RNS (RNS Number : 8659N). The content details a 'Proposed REX Retail Offer' and outlines a multi-part fundraising effort involving a Firm Placing, Conditional Placing, REX Offer, and Open Offer, all aimed at raising capital (£3.5 million via REX Offer, total minimum proceeds £6.0 million). This clearly describes a corporate action related to raising funds and changing the capital structure. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP the most specific classification over the general RNS fallback.
2024-05-09 English
Proposed Fundraise for a minimum of £6.0 million
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement from Genedrive PLC dated May 9, 2024. The primary subject is a 'Proposed Fundraise to raise a minimum of £6.0 million' via a placing, REX Offer, and Open Offer, and a 'Notice of General Meeting'. This clearly indicates an activity related to raising capital and seeking shareholder approval for that capital change. The most fitting category is 'Capital/Financing Update' (CAP). Although it mentions a 'Notice of General Meeting', the core purpose is the financing structure, not the voting results (DVA) or the proxy materials (PSI). Since it is a formal announcement detailing the structure and terms of a financing event, CAP is the best fit over the general regulatory fallback (RNS).
2024-05-09 English
Clinical Trial Agreement
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated April 24, 2024. It announces a significant business development: Genedrive entering into a Clinical Trial Agreement with a US physician organization to support FDA regulatory approval (De novo submission) for their MT-RNR1 product. The text concludes with standard disclaimers referencing RNS and the London Stock Exchange. This structure—a brief announcement of a material event, often regulatory or strategic, distributed via the RNS system—is characteristic of a general regulatory announcement that doesn't fit a more specific category like 10-K, ER, or DIV. Since it is a formal, non-specific regulatory news item distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). The document length is moderate (5995 chars), but the content is purely an announcement of an agreement, not the underlying detailed report itself.
2024-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.